Literature DB >> 3156381

Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations.

M Mason-Garcia, S Vigh, A M Comaru-Schally, T W Redding, A Somogyvari-Vigh, J Horvath, A V Schally.   

Abstract

A sensitive and specific radioimmunoassay for [6-D-tryptophan]luteinizing hormone-releasing hormone [( D-Trp6]LH-RH) was developed and used for following the rate of liberation of [D-Trp6]LH-RH from a long-acting delivery system based on a microcapsule formulation. Rabbit antibodies were generated against [D-Trp6]LH-RH conjugated to bovine serum albumin with glutaraldehyde. Crossreactivity with LH-RH was less than 1%; there was no significant crossreactivity with other peptides. The minimal detectable dose of [D-Trp6]LH-RH was 2 pg per tube. Intra- and interassay coefficients of variation were 8% and 10%, respectively. The radioimmunoassay was suitable for direct determination of [D-Trp6]LH-RH in serum, permitting the study of blood levels of the analog after single injections into normal men and after once-a-month administration of microcapsules to rats. In men, 90 min after subcutaneous injection of 250 micrograms of the peptide, serum [D-Trp6]LH-RH rose to 6-12 ng/ml. Luteinizing hormone was increased 90 min and 24 hr after the administration of the analog. Several batches of microcapsules were tested in rats and the rate of release of [D-Trp6]LH-RH was followed. The improved batch of microcapsules of [D-Trp6]LH-RH increased serum concentrations of the analog for 30 days or longer after intramuscular injection. This was accompanied by suppression of testosterone levels for more than 30 days. This radioimmunoassay should be of value for monitoring [D-Trp6]LH-RH during long-term therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3156381      PMCID: PMC397301          DOI: 10.1073/pnas.82.5.1547

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

1.  Induction of antibodies to porcine ACTH in rabbits with nonsteroidogenic polymers of BSA and ACTH.

Authors:  M Reichlin; J J Schnure; V K Vance
Journal:  Proc Soc Exp Biol Med       Date:  1968-06

2.  D-TRP5-analogue of luteinising hormone releasing hormone in combination with cyproterone acetate to treat precocious puberty.

Authors:  Z Laron; R Kauli; Z B Zeev; A M Comaru-Schally; A V Schally
Journal:  Lancet       Date:  1981-10-31       Impact factor: 79.321

3.  Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

Authors:  G Tolis; D Ackman; A Stellos; A Mehta; F Labrie; A T Fazekas; A M Comaru-Schally; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

Review 4.  LH-RH agonists and antagonists.

Authors:  A V Schally; D H Coy; A Arimura
Journal:  Int J Gynaecol Obstet       Date:  1980       Impact factor: 3.561

5.  Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone.

Authors:  J Sandow; W Von Rechenberg; G Jerzabek; W Stoll
Journal:  Fertil Steril       Date:  1978-08       Impact factor: 7.329

6.  Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules.

Authors:  T W Redding; A V Schally; T R Tice; W E Meyers
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

7.  Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma.

Authors:  K J Walker; R I Nicholson; A O Turkes; A Turkes; K Griffiths; M Robinson; Z Crispin; S Dris
Journal:  Lancet       Date:  1983-08-20       Impact factor: 79.321

8.  Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.

Authors:  J H Waxman; J A Wass; W F Hendry; H N Whitfield; G M Besser; J S Malpas; R T Oliver
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-23

9.  Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone.

Authors:  J L Barron; R P Millar; D Searle
Journal:  J Clin Endocrinol Metab       Date:  1982-06       Impact factor: 5.958

10.  From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents.

Authors:  A Corbin
Journal:  Yale J Biol Med       Date:  1982 Jan-Feb
View more
  7 in total

1.  Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats.

Authors:  Judit E Horvath; Ana M Bajo; Andrew V Schally; Magdolna Kovacs; Francine Herbert; Kate Groot
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-30       Impact factor: 11.205

2.  The effect of a synthetic GnRH analogue on catamenial epilepsy: a study in ten patients.

Authors:  J Bauer; L Wildt; D Flügel; H Stefan
Journal:  J Neurol       Date:  1992-05       Impact factor: 4.849

3.  Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.

Authors:  A V Schally; T W Redding
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

4.  Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.

Authors:  T Kadar; T W Redding; M Ben-David; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

5.  Radioimmunoassay for octapeptide analogs of somatostatin: measurement of serum levels after administration of long-acting microcapsule formulations.

Authors:  M Mason-Garcia; M Vaccarella; J Horvath; T W Redding; K Groot; P Orsolini; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

6.  Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.

Authors:  A V Schally; A I Kook; E Monje; T W Redding; J I Paz-Bouza
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

7.  Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats.

Authors:  L Bokser; B Szende; A V Schally
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.